A PILOT STUDY TO ASSESS THE FEASIBILITY OF SWITCHING, INDIVIDUALS RECEIVING ATRIPLA WITH CONTINUING CENTRAL NERVOUS SYSTEM (CNS) TOXICITY, TO A FIXED DOSE COMBINATION OF TENOFOVIR/EMTRICITABINE/RILPIVIRINE: